References
- Koh Y, Nakata H, Maeda K, Ogata H, Bilcer G, Thippeswamy D, Kincaid JF, Boross P, Wang YF, Tie Y, Volarath P, Gaddis L, Harrison RW, Weber IT, Ghosh AK, Mitsuya H. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother 2003;47:3123–3129.
- Thommes M, Baert L, van’t Klooster G, Rosier J, Kleinebudde P. Improved bioavailability of darunavir by use of κ-carrageenan versus microcrystalline cellulose as pelletization aid. Eur J Pharm Biopharm 2009;72:614–620.
- Ghebre-Sellassie I, Martin C. Pharmaceutical extrusion technology. New York: Marcel Dekker; 2003.
- Rittweger M, Arasteh K. Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 2007;46:739–756.
- Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev 1997;23:3–25.
- Van Gyseghem E, Stokbroekx S, de Armas HN, Dickens J, Vanstockem M, Baert L, Rosier J, Schueller L, Van den Mooter G. Solid state characterization of the anti-HIV drug TMC114: Interconversion of amorphous TMC114, TMC114 ethanolate and hydrate. Eur J Pharm Sci 2009;38:489–497.
- Chiou WL, Riegelman S. Pharmaceutical applications of solid dispersion systems. J Pharm Sci 1971;60:1281–1302.
- Newa M, Bhandari KH, Li DX, Kwon TH, Kim JA, Yoo BK, Woo JS, Lyoo WS, Yong CS, Choi HG. Preparation, characterization and in vivo evaluation of ibuprofen binary solid dispersions with poloxamer 188. Int J Pharm 2007;343:228–237.
- BASF. Lutrol. Product Data Sheat. 2008.
- FDA. Poloxamer 188 – oral tablets. Inactive ingredient list. LQA7B6G8JG. 2010.